Get started

Healthcare

BAX | Catch the Falling Knife | LONGBaxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services; parenteral nutrition therapies and related products; biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention; and continuous renal replacement therapies and other organ support therapies focused in the intensive care unit. It also provides connected care solutions, including devices, software, communications, and integration technologies; integrated patient monitoring and diagnostic technologies to help diagnose, treat, and manage a various illness and diseases, including respiratory therapy, cardiology, vision screening, and physical assessment; surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories. In addition, the company offers contracted services to various pharmaceutical and biopharmaceutical companies. Its products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic molecules. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.
NYSE:BAXLong
by DivergenceSeeker
3
Baxter Inc. (BAX) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the US company Baxter International Inc. (BAX). Baxter International Inc. is an American multinational healthcare company. The company primarily focuses on products to treat kidney disease, and other chronic and acute medical conditions. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 41.98 USD. According to experts, your stop-loss order should be placed at 37.35 USD if you decide to enter this position. U.S. scientific instruments maker Thermo Fisher Scientific Inc and South Korea's Celltrion Inc are among those competing to acquire the biopharma solutions business of medical device maker Baxter International Inc, according to people familiar with the matter. The divestment, which the sources said could fetch more than $4 billion, would help Baxter pay down debt following its $10.5 billion acquisition of medical device maker Hill-Rom Holdings in 2021. Baxter, which has a market value of $19 billion, had total debt of $16.6 billion as of the end of December. Private equity firms, including KKR & Co and Carlyle Group, have also expressed interest in the Baxter business, the sources said. Other bidders could still emerge, they added. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
NYSE:BAXLong
by legacyFXofficial
Bayer AG (BAYN.de) bullish scenario:The technical figure Falling Wedge can be found in the daily chart in the German company Bayer AG (BAYN.de). Bayer AG is a German multinational pharmaceutical and biotechnology company and one of the largest pharmaceutical companies in the world. Headquartered in Leverkusen, Bayer's areas of business include pharmaceuticals; consumer healthcare products, agricultural chemicals, seeds and biotechnology products. The Falling Wedge broke through the resistance line on 22/03/2023. If the price holds above this level, you can have a possible bullish price movement with a forecast for the next 9 days towards 60.750 EUR. According to experts, your stop-loss order should be placed at 54.890 EUR if you decide to enter this position. Bayer AG plans to spend $1 billion on drug research and development in the U.S. this year as it works to double its sales in the country by the end of the decade, Bayer's top U.S. pharmaceutical executive told Reuters. Sebastian Guth, president of Bayer's pharmaceuticals business in the Americas, in an interview with Reuters, said the company increased U.S. employees working on marketing for its pharmaceutical business by around 50% over the last three years and plans to expand on that by another 75% by 2030. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals and cannot be held liable nor guarantee any profits or losses.
XETR:BAYNLong
by legacyFXofficial
BMY | Time to Load | LONGBristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
NYSE:BMYLong
by DivergenceSeeker
1
CI | A Great Pick | LONGThe Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers. The company's Cigna Healthcare segment offers medical, pharmacy, behavioral health, dental, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as individual health insurance plans; and health care coverage in its international markets, as well as health care benefits for mobile individuals and employees of multinational organizations. The company also offers permanent insurance contracts sold to corporations to provide coverage on the lives of certain employees for financing employer-paid future benefit obligations. It distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was formerly known as Cigna Corporation and changed its name to The Cigna Group in February 2023. The Cigna Group was founded in 1792 and is headquartered in Bloomfield, Connecticut.
NYSE:CILong
by DivergenceSeeker
1
Life Health Care group showing strong upside to R21.39 WARNINGW Formation since Sep 2022. It's been moving in a sideways range without any promising direction. Then in February we had a breakaway gap. This is where the price jumped from the sideways range into an uptrend. And most sellers and stop losses were hit. This showed strong upside to come. 7>21>200 RSI>50 Target R21.39 WARNING Gaps like to close 70% of the time. And I don't generally like taking any trades where there are prior gaps. I'd take this trade as a medium probability one.
JSE:LHCLong
by Timonrosso
could earnings disappoint tommorow?technically the bull move in this stock has left much to be desired in terms of sustainability and stability. huge moves like this have been historically quite bearish for the stock. my estimate is that the price needs major support from a catalyst like earnings or a special response from investors while even a lackluster earnings beat could disappoint bulls. if longs want to hold this price above the $2 range they need to form a continuation pattern immediately or develop sustaining momentum to keep this move up alive. im anticipating much decline in absence of this.
NASDAQ:CDIOShort
by cerealpatterns
6
Fresenius (FRE.de) bearish scenario:The technical figure Channel Up can be found in the daily chart in the German company Fresenius SE & Co. KGaA (FRE.de). Fresenius SE & Co. KGaA is a European multinational healthcare company. It provides products and services for dialysis in hospitals and inpatient and outpatient medical care. It is involved in hospital management and in engineering and services for medical centers and other healthcare facilities. Channel Up broke through the support line on 24/02/2023. If the price holds below this level, you can have a possible bearish price movement with a forecast for the next 15 days towards 24.00 EUR. According to experts, your stop-loss order should be placed at 29.710 EUR if you decide to enter this position. Fresenius SE is exploring steps to relinquish control of its dialysis subsidiary as Elliott Investment Management puts pressure on the German healthcare company to simplify its business. Risk Disclosure: Trading Foreign Exchange (Forex) and Contracts of Difference (CFD's) carries a high level of risk. By registering and signing up, any client affirms their understanding of their own personal accountability for all transactions performed within their account and recognizes the risks associated with trading on such markets and on such sites. Furthermore, one understands that the company carries zero influence over transactions, markets, and trading signals, therefore, cannot be held liable nor guarantee any profits or losses.
XETR:FREShort
by legacyFXofficial
Afrocentric breakaway and up and away to R5.93W Formation formed on Afrocentric. The price broke above the neckline showing there's more demand. Before that there was a big GAP. This gap is known as a breakway away. It broke out of the down/sideways trend and into an uptrend. Hence there is a bullish tone and more buying along the way. 7>21>200 RSI>50 Bullish Target R5.93 ABOUT AfroCentric Investment Corporation Limited (Founded in 2008) is a South African healthcare company listed on the Johannesburg Stock Exchange. Their goal is to provide affordable, accessible healthcare to all South Africans. They operate through three main subsidiaries: Medscheme, Pharmacy Direct, and AfroCentric Health. Medscheme is one of South Africa's leading medical scheme administrators, managing over 3.5 million lives across multiple medical schemes. Pharmacy Direct is a retail pharmacy network that operates in several provinces across South Africa, offering a range of healthcare products and services. AfroCentric Health provides a range of healthcare services, including primary healthcare, occupational health, and wellness programs, to individuals and corporations.
JSE:ACTLong
by Timonrosso
Mediclinic rare formation showing upside to R135.18 with warningRising Wedge has formed with upside. This is a rare formation. Reason why it's a wedge and not a pennant is because the formation is bigger than 1 month. Above is a Rising Wedge in an uptrend. This is one of the rare formations where the price makes higher lows and higher highs - but within a consolidation after a big move up. We can either expect the price to break above and head to the next high of the target of R135.18 Or we can expect the price to break down due to bubble fears and the price will drop to the previous low (below the flag pole) at R72.24. My bias is bullish as the technicals are showing upside such as: 7>21>200 MA - Bullish RSI has formed a Falling wedge with an up flagpole. If it breaks up, it will head back to X>70 - Bulllish Target up - R135.18 ABOUT MEDICLINIC Mediclinic (Est. 1983 in SA Stellenbosch) is an international private healthcare services group with operations in South Africa, Switzerland, and the United Arab Emirates (UAE). It's listed on the London Stock Exchange, the Johannesburg Stock Exchange, and the Namibian Stock Exchange. The group has over 77 hospitals and 47 clinics, as well as a number of retail pharmacies and occupational health and wellness services. The company employs over 34,000 people worldwide. Mediclinic's largest shareholder is Remgro Limited, a South African investment company.
MLong
by Timonrosso
CNC | Oversold Healthcare Co. | LONGCentene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.
NYSE:CNCLong
by DivergenceSeeker
1
ABBV | Loading this Drug Company | LONGAbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
NYSE:ABBVLong
by DivergenceSeeker
2